Induction chemotherapy with cisplatin plus capecitabine versus cisplatin plus fluorouracil followed by concurrent chemoradiotherapy with cisplatin in locally advanced nasopharyngeal carcinoma
QI Bin
XU Wen-shen
YIN Wen-jing
LIU Jin-quan
CHEN Dong-ping
YU Yi
LI Ming-yi
LI Zhou-yu
HE Lu
LIN Ling
HUANG Zhong
Abstract：Objective To evaluate the clinical outcomes and adverse effects of induction chemotherapy with cisplatin plus capecitabine (PX regimen) through compare to induction chemotherapy with cisplatin plus fluorouracil (PF regimen) followed by concurrent chemoradiotherapy with cisplatin in locally advanced nasopharyngeal carcinoma (NPC). Methods Stage III-IVa NPC patients were randomized allocated to PX or PF group. The induction chemotherapy regimen in PX group was cisplatin (80 mg/m2 d1) plus capecitabine (1 000 mg/m2, twice a day, d1-14), while in PF group was cisplatin (80 mg/m2 d1) plus fluorouracil (800 mg/m2/day, continuous intravenous 120 h). After two cycles of induction chemotherapy (every 3 weeks), patients in both groups received concurrent chemoradiotherapy with cisplatin (100 mg/m2 d1, every 3 weeks). Clinical outcomes and adverse effects were compared between the two groups. Results Between January 1, 2015 and March 1, 2017, 246 patients were enrolled in trial, 123 in each group. The progress-free survivals (PFSs) were 83.2％ (95％ CI: 74.8-91.6) and 80.3％ (95％ CI: 72.1-88.5) in PX group and PF group, respectively. The overall survivals (OSs) were 92.4％ (95％ CI: 85.9-98.9) and 91.1％ (95％ CI: 85.0-97.2) in PX group and PF group, respectively. There was no statistically significant difference between the 2 groups. Neutropenia was the most common Grade 3-4 adverse event. Conclusion PX regimen as induction chemotherapy for locally advanced NPC patients is not inferiority than PF regimen with tolerable adverse events.
Keywords：nasopharyngeal carcinomainduction chemotherapycapecitabinecisplatinfluorouracil
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 374-378 )